TIVUBIQ Trademark

Trademark Overview


On Wednesday, February 19, 2020, a trademark application was filed for TIVUBIQ with the United States Patent and Trademark Office. The USPTO has given the TIVUBIQ trademark a serial number of 88802061. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, March 7, 2022. This trademark is owned by Celgene Corporation. The TIVUBIQ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use that modulate the immune system
tivubiq

General Information


Serial Number88802061
Word MarkTIVUBIQ
Filing DateWednesday, February 19, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, March 7, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 8, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use that modulate the immune system

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSunday, February 23, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events


Event DateEvent Description
Monday, March 7, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, March 7, 2022ABANDONMENT - NO USE STATEMENT FILED
Tuesday, August 3, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 8, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 8, 2021PUBLISHED FOR OPPOSITION
Wednesday, May 19, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, May 6, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, May 6, 2021EXAMINER'S AMENDMENT ENTERED
Thursday, May 6, 2021NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, May 6, 2021EXAMINERS AMENDMENT E-MAILED
Thursday, May 6, 2021EXAMINERS AMENDMENT -WRITTEN
Friday, October 23, 2020NOTIFICATION OF FINAL REFUSAL EMAILED
Friday, October 23, 2020FINAL REFUSAL E-MAILED
Friday, October 23, 2020FINAL REFUSAL WRITTEN
Tuesday, September 29, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, September 28, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, September 28, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, March 29, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sunday, March 29, 2020NON-FINAL ACTION E-MAILED
Sunday, March 29, 2020NON-FINAL ACTION WRITTEN
Sunday, March 29, 2020ASSIGNED TO EXAMINER
Sunday, February 23, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, February 22, 2020NEW APPLICATION ENTERED IN TRAM